NCT02998606View on ClinicalTrials.gov

Movantik for Opioid-Related Esophageal Disorders

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions

Opioid-Induced DisordersEsophagus Disorder

Interventions

DRUG

Naloxegol

MOVANTIK™ 25 mg, daily

DRUG

Placebo Oral Capsule

Placebo 25 mg, daily

Trial Locations (1)

19140

Temple University, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Temple University

OTHER